Literature DB >> 20004482

Changes in hypothalamic-pituitary-thyroid axis following successful treatment with low-frequency right prefrontal transcranial magnetic stimulation in treatment-resistant depression.

Shinsuke Kito1, Takashi Hasegawa, Kenichi Fujita, Yoshihiko Koga.   

Abstract

Hypothalamic-pituitary-thyroid (HPT) axis abnormalities have been reported in some patients with major depression. To knowledge, however, the effects of low-frequency right prefrontal transcranial magnetic stimulation (TMS) on the HPT axis have not yet been elucidated. The goal of this study was to evaluate alterations in the HPT axis associated with the therapeutic efficacy of TMS treatments. Twenty patients with treatment-resistant depression received five 60-s 1-Hz trains over the right dorsolateral prefrontal cortex. Twelve treatment sessions were administered within a 3-week period (total pulses, 3600). Responders were defined as a > or =50% decrease in the Hamilton Depression Rating Scale (HDRS) score. Serum levels of thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), and free thyroxine (fT4) were measured, respectively, at pre- and post-treatment. There were no significant changes in fT3 and fT4 levels measured at either pre- or post-treatment in either responders or nonresponders; however, TSH levels of responders elevated significantly after TMS treatments. In addition, there was a significant negative correlation between TSH levels at pretreatment and decrease (%) in the HDRS score. These findings suggest that the HPT axis is associated with antidepressant effects of low-frequency right prefrontal TMS, and indicate that lower TSH levels at pre-treatment are correlated with better therapeutic efficacy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20004482     DOI: 10.1016/j.psychres.2008.10.002

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

Review 1.  Biological markers in noninvasive brain stimulation trials in major depressive disorder: a systematic review.

Authors:  Thiago M Fidalgo; J Leon Morales-Quezada; Guilherme S C Muzy; Noelle M Chiavetta; Mariana E Mendonca; Marcus V B Santana; Oscar F Goncalves; Andre R Brunoni; Felipe Fregni
Journal:  J ECT       Date:  2014-03       Impact factor: 3.635

Review 2.  Subclinical thyroid dysfunction and major depressive disorder.

Authors:  Grigorios N Karakatsoulis; Eva-Maria Tsapakis; Calypso Mitkani; Konstantinos N Fountoulakis
Journal:  Hormones (Athens)       Date:  2021-08-24       Impact factor: 2.885

Review 3.  Predictors of Response to Repetitive Transcranial Magnetic Stimulation in Depression: A Review of Recent Updates.

Authors:  Sujita Kumar Kar
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-02-28       Impact factor: 2.582

4.  Repetitive Transcranial Magnetic Stimulation (rTMS) Modulates Thyroid Hormones Level and Cognition in the Recovery Stage of Stroke Patients with Cognitive Dysfunction.

Authors:  Hong Li; Jiang Ma; Jun Zhang; Wan-Ying Shi; Hao-Nan Mei; Yan Xing
Journal:  Med Sci Monit       Date:  2021-10-23

5.  The relationship between brain oscillatory activity and therapeutic effectiveness of transcranial magnetic stimulation in the treatment of major depressive disorder.

Authors:  Andrew F Leuchter; Ian A Cook; Yi Jin; Bill Phillips
Journal:  Front Hum Neurosci       Date:  2013-02-26       Impact factor: 3.169

6.  Approaches to understanding and addressing treatment-resistant depression: a scoping review.

Authors:  Emily Jenkins; Elliot M Goldner
Journal:  Depress Res Treat       Date:  2012-04-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.